Wave Life Sciences Ltd (WVE) — Cash Flow-to-Debt Ratio
Wave Life Sciences Ltd (WVE) has a Cash Flow-to-Debt Ratio of -0.83x as of March 2026, meaning its operating cash flow of $-59.55 Million could theoretically repay -1% of its total liabilities ($71.81 Million) in one year. See WVE free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wave Life Sciences Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Wave Life Sciences Ltd across 13 annual periods. Also explore Wave Life Sciences Ltd (WVE) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Wave Life Sciences Ltd (2013–2025)
Year-by-year debt coverage analysis for Wave Life Sciences Ltd. For market capitalisation and broader financial context, see Wave Life Sciences Ltd (WVE) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.67x | $-187.49 Million | $112.27 Million | ▼ -57.8% |
| 2024 | -1.06x | $-151.03 Million | $142.69 Million | ▼ -1181.8% |
| 2023 | -0.08x | $-19.43 Million | $235.32 Million | ▲ +87.6% |
| 2022 | -0.67x | $-127.78 Million | $191.48 Million | ▼ -30.9% |
| 2021 | -0.51x | $-88.99 Million | $174.51 Million | ▲ +17.1% |
| 2020 | -0.62x | $-115.98 Million | $188.59 Million | ▲ +30.5% |
| 2019 | -0.89x | $-188.23 Million | $212.64 Million | ▼ -761.9% |
| 2018 | -0.10x | $-22.86 Million | $222.59 Million | ▲ +94.8% |
| 2017 | -1.99x | $-83.67 Million | $42.03 Million | ▼ -87.1% |
| 2016 | -1.06x | $-31.87 Million | $29.95 Million | ▼ -1.4% |
| 2015 | -1.05x | $-12.53 Million | $11.93 Million | ▲ +78.4% |
| 2014 | -4.86x | $-4.43 Million | $911.00K | ▼ -1279.8% |
| 2013 | -0.35x | $-3.55 Million | $10.09 Million | — |